- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01624727
Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)
Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Study Design: This is a randomized, parallel study design with a usual care control group. 278 subjects with coronary heart disease (CHD) are being randomized to omega-3 supplementation or standard of care (139 in each arm).
Multidetector computed tomographic angiography (MDCTA) is performed at baseline to quantitate the amount of noncalcified and calcified coronary plaque and again at 30 month follow-up to determine if there has been a change in the volume of noncalcified or total plaque. The primary endpoint is change in coronary noncalcified plaque volume during the 30 months of intervention between active and standard of care.
Hypothesis: Percent change in progression of coronary plaque volume will be less for the omega-3 fatty acid intervention compared to standard of care.
Secondary endpoints include plasma levels of inflammatory markers, lipids and measures of insulin sensitivity.
Secondary outcomes include testing the hypothesis that targeting inflammation with omega-3 fatty acids will be associated with:
- Change in total plaque volume per patient.
- improvement in physical function and exercise and reduction in pain and stiffness as measured by the WOMAC questionnaire
- Reduction of mediators of inflammation in the circulation including CRP, PAI-1, serum amyloid A, MMP-9 and fibrinogen, pro-inflammatory cytokines including IL-6, TNF-a and IL-1b, the adhesion molecules VCAM-1 and ICAM-1, increase in adiponectin and reduction in serum nitrotyrosine as a marker of oxidative stress.
- Reduction of insulin resistance assessed by fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR).
- Reduction of inflammation in the liver associated with nonalcoholic steatohepatitis (NASH), a newly recognized component of the metabolic syndrome, and reduction of fatty liver quantitated by computerized tomography and levels of AST and ALT as markers of liver inflammation related to NASH.
- Investigation of the relationship between vitamin D status and coronary plaque progression as well as with insulin resistance (HOMA-IR), beta-cell function (HOMA-%beta) and inflammatory cytokines.
- Determination of whether baseline vitamin D levels predict clinical response to the omega-3 fatty acid intervention, and whether hypovitaminosis D is associated with plaque progression.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Beth Israel Deaconess Medical Center
-
Milton, Massachusetts, Förenta staterna, 02186
- South Shore Medical Group
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- coronary artery disease
- previous myocardial infarction
- angioplasty (> 6 months ago)
- previous coronary bypass surgery (> 12 months ago)
- stable angina
- non-calcified plaque on prior CT
- abnormal exercise tolerance test
- aged 21- 80 years
- BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI > 24.5 for subjects from Asian origin)
- stable dose of statin for 1 month at screening or unable to tolerate a statin
- normal renal function - estimated creatinine clearance calculated using Cockcroft-Gault (CG) equation ≥60 at screening [eCrCLCG (ml/min) = [(140 - age) x weight (kg)]/[SCr(mg/dl) x 72] x [0.85 if female] or serum Cr < 1.3
- ALT, AST) < 3 times upper limits of normal)
- normal thyroid function or on stable dose replacement therapy
- an ETT performed within 12 months prior
Exclusion criteria
- unstable angina (increase in frequency or severity of anginal episodes or development of chest pain at rest)
- significant obstructive disease in left main coronary artery, ostial LAD or newly diagnosed three-vessel disease since prior cardiac catheterization by MDCTA
- significant heart failure (NYHA class III and IV)
- Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome
- allergy to beta-blocker in subjects with resting heart rate > 65 bpm
- systolic blood pressure > 160 mm Hg
- diastolic BP > 100 mm Hg
- persons with allergies to iodinated contrast material or shellfish
- allergy to nitroglycerin
- history of asthma only if unable to tolerate beta-blockers
- BMI > 35 kg/m2 if female and > 40 kg/m2 if male
- body weight > 350 lbs
- Use of drugs for weight loss [eg Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the-counter medications] within three months of screening
- surgery within 30 days of screening
- history of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
- poor mental function or history of dementia/Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)] or any other reason to except patient difficulty in complying with the requirements of the study
- medicine for erectile dysfunction within 72 hours prior to MDCTA
- Prior stroke with residual cognitive deficit or functional deficit preventing any type of exercise
- Current chemotherapy or radiation for malignancy
- Current weekly alcohol consumption > 21 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)
Exclusions based on nuclear imaging:
- Transient cavity dilation
- More than one vascular territory involved with reversible defect (multiple defects)
- Reversible defects involving the anterior wall, septum or apex (LAD territory)
Exclusions based on echocardiography imaging:
1. More than one vascular territory involved with inducible wall motion abnormalities (multiple defects) 2. Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD territory)
-
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Inget ingripande: Usual care
Those randomized to usual care will continue to follow the care provided by their cardiologist.
They will have all the follow-up phone calls, visits and testing which the intervention group has.
|
|
Aktiv komparator: Lovaza (Omega 3 ethyl esters)
|
Lovaza 3.6 g daily
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The primary endpoint is change in coronary noncalcified plaque volume.
Tidsram: Baseline and 30 months
|
MDCTA is performed at baseline to quantitate the amount of noncalcified and calcified coronary plaque and again at 30 month follow-up to determine if there has been a change in the volume of noncalcified or total plaque.
The primary endpoint is change in coronary noncalcified plaque volume during the 30 months of intervention between active and standard of care.
The hypothesis is that those on Lovaza will have less progression of coronary plaque compared to those in usual care.
|
Baseline and 30 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Coronary artery plaque assessment
Tidsram: Baseline and 30 months
|
|
Baseline and 30 months
|
Effect of Lovaza on Physical Function, Pain, Stiffness and Exercise
Tidsram: Baseline and 1 year
|
Those on Lovaza will have better physical function and less pain and stiffness as assessed by the WOMAC questionnaire and more minutes of exercise per week compared to control
|
Baseline and 1 year
|
Inflammatory markers
Tidsram: Baseline and 30 months
|
Compared to usual care, those on Lovaza will have reduction of mediators of inflammation in the circulation, including CRP, PAI-1, serum amyloid A, MMP-9 and fibrinogen, pro-inflammatory cytokines including IL-6, TNF-a and IL-1b, the adhesion molecules VCAM-1 and ICAM-1, increase in adiponectin and reduction in serum nitrotyrosine as a marker of oxidative stress.
Additional inflammatory markers may be identified in the future and measured.
|
Baseline and 30 months
|
Pericardial Fat
Tidsram: Baseline and 30 months
|
The amount of pericardial fat will be quantitated by CT at baseline and 30-month follow-up.
The percent change between the two time-frames will be measured.
Those on Lovaza and/or those who have lost weight will have a reduction (or lack of increase) in pericardial fat at 30-months compared to those in usual care.
|
Baseline and 30 months
|
Insulin Resistance
Tidsram: Baseline and 30 months
|
Insulin resistance will be assessed by fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) at baseline and 30-months in the two study groups.
|
Baseline and 30 months
|
Nonalcoholic steatohepatitis (NASH)
Tidsram: Baseline and 30 months
|
Reduction of inflammation in the liver associated with nonalcoholic steatohepatitis (NASH), a component of the metabolic syndrome, and reduction of fatty liver quantitated by computerized tomography and levels of AST and ALT as markers of liver inflammation related to NASH.
|
Baseline and 30 months
|
Vitamin D Levels and coronary plaque progression
Tidsram: Baseline and 30 months
|
|
Baseline and 30 months
|
Cognitive function
Tidsram: Baseline, 1 year and 30-months
|
To determine if those on Lovaza have less decline in cognitive function at 1 year and 30 months of follow-up compared to those in the usual care group.
|
Baseline, 1 year and 30-months
|
Exercise capacity and coronary plaque
Tidsram: Baseline
|
To determine if exercise capacity correlates with coronary plaque measurements.
The hypothesis is that those with better exercise capacity will have lower amounts of coronary plaque.
|
Baseline
|
Urinary microalbumin and coronary plaque
Tidsram: Baseline and 30-months
|
At baseline, subjects with lower urinary microalbumin will have lower amounts of coronary plaque.
Those taking Lovaza will have less increase in urinary microalbmumin at 30-month follow-up compared to those in usual care.
|
Baseline and 30-months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Francine K Welty, MD, PhD, Beth Israel Deaconess Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Welty FK, Schulte F, Alfaddagh A, Elajami TK, Bistrian BR, Hardt M. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B(4). FASEB J. 2021 Apr;35(4):e21448. doi: 10.1096/fj.202002471R.
- Malik A, Ramadan A, Vemuri B, Siddiq W, Amangurbanova M, Ali A, Welty FK. omega-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial. Am J Clin Nutr. 2021 May 8;113(5):1168-1176. doi: 10.1093/ajcn/nqaa420.
- Malik A, Kanduri JS, Asbeutah AAA, Khraishah H, Shen C, Welty FK. Exercise Capacity, Coronary Artery Fatty Plaque, Coronary Calcium Score, and Cardiovascular Events in Subjects With Stable Coronary Artery Disease. J Am Heart Assoc. 2020 Apr 7;9(7):e014919. doi: 10.1161/JAHA.119.014919. Epub 2020 Mar 26.
- Alfaddagh A, Elajami TK, Saleh M, Mohebali D, Bistrian BR, Welty FK. An omega-3 fatty acid plasma index >/=4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. Atherosclerosis. 2019 Jun;285:153-162. doi: 10.1016/j.atherosclerosis.2019.04.213. Epub 2019 Apr 13.
- Alfaddagh A, Elajami TK, Ashfaque H, Saleh M, Bistrian BR, Welty FK. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial. J Am Heart Assoc. 2017 Dec 15;6(12):e006981. doi: 10.1161/JAHA.117.006981.
- Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. J Am Heart Assoc. 2017 Jul 14;6(7):e004740. doi: 10.1161/JAHA.116.004740.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2006P000175
- P50HL083813 (NIH)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metaboliskt syndrom
-
Grand Valley State UniversityAnmälan via inbjudanMetabolic Associated-dysfunction Steatotic Lever Disease (MASLD) | Metabolic Associated-dysfunction Steatohepatit (MASH)Förenta staterna
-
Scripps Whittier Diabetes InstituteAvslutadCardio-metabolic Care-Team Intervention (CMC-TI)
-
Shanghai General Hospital, Shanghai Jiao Tong University...Har inte rekryterat ännuPrediabetes | Kontinuerlig glukosövervakning | Metabolic Management Center
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
TJ Biopharma Co., Ltd.Rekrytering
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RekryteringMyelodysplastiska syndrom (MDS)Förenta staterna, Israel
-
AbbVieCelgene; Genentech, Inc.AvslutadMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Tyskland
-
AbbVieGenentech, Inc.Aktiv, inte rekryterandeMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Kanada, Frankrike, Tyskland, Italien, Storbritannien
Kliniska prövningar på Omega 3 acid ethyl esters
-
University of IowaGlaxoSmithKlineAvslutadKardiovaskulär sjukdomFörenta staterna
-
RDC Clinical Pty LtdAvslutadOptimal gastrointestinal absorption av Omega-3Australien
-
Arizona State UniversityAvslutad
-
Institute for Clinical and Experimental MedicineRekryteringKetos | Akut hjärtsvikt | Hemodynamisk instabilitet | Syndrom med lågt hjärtminutvolymTjeckien
-
McGill UniversityCanadian Institutes of Health Research (CIHR)AvslutadMuskelatrofi | Kognitiv funktion | Muskelproteinsyntes | Insulinkänslighet | Muskelstyrka | Funktionell kapacitet | Fysisk inaktivitet | Mitokondriell funktionKanada
-
Shanghai Yueyang Integrated Medicine HospitalOkänd
-
University of WashingtonJanssen Research & Development, LLCAvslutadKastrationsresistent prostatakarcinom | Metastaserande prostatakarcinom | Prostata Adenocarcinom | Steg IV prostatacancer AJCC v8 | Steg IVA prostatacancer AJCC v8 | Steg IVB prostatacancer AJCC v8 | Dubbelnegativt prostatakarcinomFörenta staterna
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Medical Research Foundation, OregonAvslutadProstatakarcinom | Hälsostatus okändFörenta staterna
-
M.D. Anderson Cancer CenterRekryteringHematopoetisk och lymfoid cellneoplasma | Återkommande akut myeloid leukemi | Återkommande myelodysplastiskt syndrom | Refraktär Akut Myeloid Leukemi | Refraktärt myelodysplastiskt syndrom | Återkommande akut bifenotypisk leukemi | Refraktär Akut Bifenotypisk LeukemiFörenta staterna
-
Centre Leon BerardOncoTherapy Science, Inc.Avslutad